or disappear over several years, some may undergo cancerous transformation into brain gliomas. [9] [10] [11] [12] [13] [14] [15] [16] [17] The mechanism of NBOs development is still unclear. Epilepsy is one of the most common complications of NF1, with the prevalence approximately from 4.2% to 6% in NF1 patients. 3, 18, 19 The much higher incidence of epilepsy in NF1 patients may be related to the coexistence of intracranial tumors or NBOs. [18] [19] [20] This retrospective study analyzed the clinical features and MRI characteristics of 630 NF1 patients to clarify the relationship of epilepsy and intracranial lesions.
Subjects and methods
We performed a retrospective analysis on clinical data of 630 patients who were diagnosed as having NF1 in our hospital from January 1986 to December 2006. The diagnosis of NF1 was confirmed by 2 neurologists (Drs. Hsieh and Wu) according to the National Institutes of Health Consensus Conference criteria. 1 The inclusion criteria included 2 or more of the following:
Six or more café -au-lait spots. Two or more neurofibromas. Skin-fold freckling in the axilla or groin. Optic glioma. Two or more Lisch nodules. A distinctive bony lesion such as dysplasia of the sphenoid bone or thinning of a long-bone cortex. A first-degree relative (parent, sibling, or offspring) with NF1 diagnosed using the above criteria.
Patients with NF2 or other neurocutaneous diseases that were misdiagnosed as NF1 were excluded.
Patients with epileptic seizure were defined as ''having 1 or more unprovoked clinically defined seizures and consuming antiepileptic drugs.'' This stringent definition was employed for the usage of antiepileptic therapy should be recorded in one's medical history in order to ensure high reliability of the diagnosis of epilepsy. With this definition, 37 NF1 patients were found to have epileptic seizures. Additionally, encephaloelectrography (EEG) was used to confirm the diagnosis of seizure in 35 out of MRI of brain, head, and neck was performed to delineate the intracranial lesions. The indications for these MRI studies were not confined to the neuroimaging investigation of NF1, but include stroke, seizure, mental retardation, or other symptoms such as blurred vision, headache, and focal weakness. The MRIs were evaluated by 2 neuroradiologists (CJ Wang and SC Chin) and 2 neurologists. The number and distribution of intracranial tumors and any focal hyperintensities of T2-weighted signals, and the hypo-or iso-intensities of T1-weighted signals on MRI, were reviewed. Patients were assigned into 2 groups (with epilepsy and without epilepsy) for analysis. The locations of NBOs were classified into 4 major areas: cortical area (including hippocampus and amygdala), subcortical white matter, basal ganglia, and infratentorial area (including cerebellum and brain stem). x 2 tests were used to determine the correlation of various locations of NBOs and the prevalence of epileptic seizure in NF1 patients. Statistical analysis was performed with SPSS ver. 15. The significance level was defined as p < 0.05.
Results
Six hundred and thirty patients (332 males and 298 females) were confirmed as having NF1 in CGMH. Their mean age was 29.5 AE 19.0 years. This series comprised a total of 172 patients (75 females [43.6%] and 97 males [56.4%]) who had MRI studies of the brain, or head and neck. We calculated intracranial lesions based on those who underwent MRI studies.
In 630 patients diagnosed as having NF1, 37 (5.9%) were ascertained to have had 1 or more unprovoked seizures and have taken antiepileptic drugs. The clinical manifestations of these NF1 patients with epileptic seizures are depicted in Table 1 . No familial history of epilepsy was reported in this group of patients (22 males [59.5%] and 15 females [40.5%]). The mean age at onset of seizures was 14.8 years (2 months to 72 years). The periods of 37 followed patients was 68.4 AE 46.5 months (1-228 months), and mean duration of using antiepileptic drugs was 54.8 AE 50.1 months (1-228 months). There were 21 (56.8%) patients received antiepileptic monotherapy and 16 (43.2%) patients with polytherapy. Seventeen of the 30 were seizure free (7 patients off and 10 patients on antiepileptic medication), 7 had 5 seizures per year, and 6 patients had >5 seizures per year.
The most common seizure pattern was primary partial onset seizure (PS) (n = 17). Among this partial-onset seizure group, the seizure pattern of 14 patients was classified as complex partial seizures (CPS) and 6 had secondary generalization. Other patterns found included 2 absence seizures (AS) and 2 infantile spasms. In 35 patients who had 1 or more EEG recording, 24 (68.6%) had recorded epileptiform discharges: 12 had discharges localized in the unilateral hemisphere and the other 12 had multifocal discharges (involved bilateral hemispheres), including 3 Hz generalized spike-and-wave complexes in 2 patients. Two patients had no EEG data but were diagnosed as having epilepsy from clinical history or presentations.
Twenty-three (62.2%) of the 37 NF1 patients with epilepsy had MRI of the brain or head and neck. Four patients were found to have brain tumors, including 1 meningioma and 3 supratentorial gliomas. Other tumors such as optic pathway glioma and pituitary adenoma were also noted. Sixteen (69.6%) patients had focal areas of prolonged T2-weighted signals on MRI, which we called NBOs.
The common locations of NBOs were the basal ganglia, cerebellum, brain stem, and subcortical white matter (Tables 1 and 2 ).
Of the 593 NF1 patients without epilepsy, 149 (25.1%) received MRIs. The neuroimaging findings include 108 (71.8%) NBOs and 7 (5.4%) intracranial tumors (3 meningiomas and 4 gliomas) that may be related to seizure (Table 2 ).
Discussion
NF1 was previously considered a disease with peripheral manifestations, such as café -au-lait spots, peripheral neurofibromas, Lisch nodules, and axillary freckling.
1-3 Diagnosis of NF1 is typically made during childhood, based on clinical findings. A positive family history is noted in about 50% of cases. The consensus among the experts indicates that patients with NF1 have not only peripheral lesions such as a subcutaneous mass or neurofibroma but also some CNS lesions 5 such as optic pathway glioma. Moreover, NF1 patients have a higher incidence of tumors than the general population. 2, 3 The incidence of abnormalities (tumor, NBOs, or both) in brain MRIs was as high as 80.1% in our series, which suggests that the brain imaging study is essential in investigating the presence of any intracranial lesion in each NF1 patient, whether or not he or she had neurological deficits of CNS.
One of the most common complications of NF1 is seizure. Roughly 4.2-6% of NF1 patients have epileptic seizures, with the prevalence approximately twice of that in the general population. 18, 19 In fact, seizure could be the first presentation in NF1
patients. Riccardi, Friedman, and Birch reported epileptic seizure prevalence of 5% and 6.4% 3, 18, 19 in the NF1 population. Previous reports showed that the lifetime prevalence of epilepsy is higher in patients with NF1 compared with the general population. 19 The exact prevalence of epilepsy in the NF1 population is difficult to determine because of the following reasons: first, the subtlety of partial onset seizure might be ignored during the devastating course of the illness. Second, there are different criteria for defining seizures, as have been used in previous studies. Some authors only took account of unprovoked seizures 19 in computing the prevalence, whereas other authors included NF1 patients with only febrile convulsion. 18 By contrast, Riccardi excluded from those NF1 patients in whom epilepsy was related to intracranial tumors. 3 We defined ''NF1 patients with epilepsy'' as those having 1 or more seizures and were taking antiepileptic drugs regardless of the aetiology of seizures. Therefore, the prevalence of unprovoked seizure in our series will probably be higher than in other studies. Thirty-seven (5.9%) patients were diagnosed as having epilepsy and were taking antiepileptic drugs in our series. The prevalence of epileptic seizures in our study is higher than that in the previous data reported by Riccardi 3 (5%) and Korf et al. 18 (4%). It is noteworthy that since antiepileptic medication use is one of the criteria for defining epileptic seizure in the present study, it may lead to the underestimation of the prevalence in our cohort. This may be explained by the bias related to the specific interest of our institute in studying plastic and orthopedic diseases in Taiwan. Riccardi briefly reported both major and minor motor seizures in NF1 patients occurring at a frequency of about 5%; the seizure type was usually primary generalization rather than being focal in nature. 3 However, Korf 18 and Kulkantrakorn 19 both reported that partial onset seizure, especially CPS with or without secondary generalization, were slightly more common than primary generalized seizures in NF1. In our series, the most common seizure was also partial onset seizure (n = 17, 46%), especially CPS (n = 14, 37.8%), followed by primary generalized seizures (n = 15, 40.5%), among which GTCS is the most common (n = 13, 35%). In addition, Kulkantrakorn 19 and Vivarelli 20 had reported 2 cases of AS, each of which had NBOs in the basal ganglia; Korf 18 also reported 1 case of AS but no NBOs. We also had 2 cases of AS (see patients 16 and 21, Table 1 ), with age of onset at 9 years and 10 years respectively. The diagnosis of childhood absence epilepsy (CAE) is confirmed according to clinical presentations and typical EEG findings. To the best of our knowledge, this is the first report to dissect the relationship between the anatomical distribution of intracranial lesions and the pattern of seizure in an NF1 cohort. We conclude that no significant correlations were found among intracranial lesions, EEG, and seizure patterns. For epileptiform discharges in EEG analysis, 5 of our patients who presented with general onset seizures (33%) had focal discharges. It is hypothesized that seizures in NF1 may progress rapidly, which may cause the witness of the events to neglect the initial symptoms or signs of partial onset seizures. Therefore, the prevalence of partial onset seizure in NF1 may have been underestimated in our series. The other explanation for the higher rate of seizures in NF1 patients is that they may have a lower threshold for the abnormal epileptiform discharges; that is, the subclinical focal discharges could evolve into clinical generalized seizure. This hypothesis is supported by the finding that neurofibromin, the protein product of the NF1 gene, is abundantly expressed in the cerebral cortex during embryonic development. In particular, neurofibromin appears to be involved both in the differentiation of the neuronal neurotransmitter phenotype and in the formation of synapses. 22 The expression of neurofibromin may result in an aberrant neural network that lowers the threshold for abnormal epileptic activity. This correlation between the particular seizure pattern and the location of discharges needs further investigation. 21, 22 Neuronal heterotopia was reported to be the cause of seizures in some NF1 patients; however, this was not found in our series. The relationship between epilepsy and brain malformation and/or neuronal migrational disorders in NF1 is not well established, compared with other neurocutaneous disorders such as tuberous sclerosis 23 or the Sturge-Weber syndrome. 25 Brain tumors in NF1 are not uncommon, but the association between intracranial tumors and epilepsy in NF1 was rarely discussed before. Vivarelli 20 reported a relatively high incidence of epileptic patients with NF1 and cerebral tumors (five of 14 patients, 35.7%). In three of these, seizures were the first clinical manifestation. But in other studies, the incidence of intracranial tumor was only 9.52% in 21 19 or 0% in 22 NF1 patients with epilepsy. 18 In this study, the overall the incidence of intracranial tumors was higher in NF1 patients with epilepsy than in those without epilepsy (see Table 2 ). Among 11 NF1 patients with intracranial tumors, 4 patients (36.36%) had epilepsy. On the other hand, there are only 19 patients (11.80%) had epilepsy in 161 NF1 patients without tumors. Lesions of optic pathway glioma, pituitary adenoma, and cerebellar tumor were not included in this analysis because special disease entity with seizure (hemifacial spasm in childhood cerebellar tumor 27, 28 and seizure in complicated pituitary adenoma 29 ) and no case description of OPG and related seizure. In previous reports, the overall frequency of NBOs in NF1 patients is 43-77%. 9, 14 In children with NF1, 93% have NBOs, which are common in ages 4-10 years. 12 The most common anatomical site is the globus pallidus (GP, 30.4%), followed by the cerebellum (23.5%) and midbrain (16.2%). 9, 14 In our previous study, NBOs were most commonly found in the GP and thalamus (15.4%), and then in the cerebellum and subcortical white matter (11.54%). 30 Notably, only few NBOs had been reported to be found in the subcortical white matter and cortex. Analyzing the locations of the NBOs in our 172 patients using MRI studies, we found that the most common location is the globus pallidus (GP), 81 (47.09%), followed by 68 in the thalamus (39.53%) and 56 in the cerebellum (32.56%). Twentythree NBOs were observed in the subcortical white matter (13.37%), 7 in the cortex (4.07%), and 32 in the hippocampus and amygdala (18.60%). The above locations of NBOs were classified into 4 major areas. The most common location is the basal ganglia (65.2% in the epileptic group and 57.7% in the nonepileptic group), and then the infratentorial area (47.8% in the epileptic group and 47.0% in the nonepileptic group) ( Table 2 ). Although it does not reach statistical significance, the number of NBOs located in the basal ganglia, cortical area, and subcortical white matter was greater in the epileptic group (65.2%, 26.1%, and 17.4%, respectively) than in the nonepileptic group (57.7%, 19.5%, and 12.8%, respectively). The basal ganglia and subcortical white matter may be relative predisposing locations in the induction of epilepsy in NF1 patients, just as the cortical area, hippocampus, and amygdala are well known to be important locations in most symptomatic seizures. Further investigation is needed to define the underlying mechanism of this observation.
No significant differences were found between the incidence of NBOs in the epileptic and the nonepileptic groups (69.6% and 72.5%). On the other hand, if we analyzed NBOs in NF1 patients, 16 patients had epilepsy (12.90%), vs. the other 7 out of 48 NF1 patients (14.58%) without NBOs. The MRIs in Fig. 1 demonstrate the presence of several NBOs in NF1 patients with and without epilepsy. In conclusion, NBOs is not considered as a contributing factor of epilepsy in NF1 patients. 19, 20 In our clinical course analysis, 24 (67.9%) out of 37 epileptic patients were well controlled on 1 or more antiepileptic drugs (groups A and B, see Table 1 ), and a total of 10 (27.0%) were advised to stop taking drugs by clinical physicians. Only 6 were poorly controlled by history, among them 1 patient who had thalamus tumor (patient 4) and another who had cerebral palsy (CP) with mental retardation (patient 10). One patient had CP (patient 14) and 1 had a history of meningitis at the age of 10 months (patient 18). There is no obvious risk factor or organic brain lesion related to the poor prognosis in the other 2 patients. Seven patients were lost to follow-up. Status epilepticus was not encountered in any patient during the follow-up period; only 1 patient had a history of epileptic partialis continuca (EPC), which was well controlled. In the analysis of medication use, no specific antiepileptic drugs were seen to be particularly effective for NF1 patients with epilepsy. In our series, 21 patients were able to have good seizure control response using a single drug therapy, while 16 were on polytherapy. The prognosis of epilepsy in our NF1 patients is satisfying that more than half of patients could be controlled by only 1 antiepileptic drug and majority of the patients will be seizure free. This finding is similar to previous studies, 19, 20 and better than the prognosis of tuberous sclerosis (20-25% patients were drug resistant) 24 and Sturge-Weber syndrome (50% patients had status epilepticus).
25,26
Conclusion
From our study, the occurrence of epileptic seizures in NF1 patients is related to intracranial tumors (supratentorial meningioma or glioma) but not to NBOs. In this study, most patients with brain lesions did not present with seizures. Our findings suggest that most of the brain lesions, either tumors or NBOs, in NF1 patients are often silent and asymptomatic. The positive finding rate with MRI is 74.4% in this study. Therefore, neuroimaging study for patients with NF1 is essential to determine the existence of any intracranial lesion that may need further medical attention.
